alla rilevanza dei metaboliti MT1 (N-tert-butil-6-cloro-1,3,5-triazina-2,4-diammina), MT13 (4-(tert-butilammino)-6-(etilammino)-1,3,5-triazin-2-olo oppure 6-idrossi -N2-etil-N4- tert-butil-1,3,5-triazina-2,4-diammina), MT14 (4-ammino 6(tert-butilammino)-1,3,5-triazin-2-olo oppure N-tert-butil-6-idrossi-1,3,5-triazina-2,4-diammina), e dei metaboliti non identificati LM1, LM2, LM3, LM4, LM5 e LM6 rispetto al cancro, se la terbutilazina è classificata, ai sensi del regolamento (CE) n. 1272/2008 come «sospettata di provocare il cancro».
the relevance of the metabolites MT1 (N-tert-butyl-6-chloro-1,3,5-triazine-2,4-diamine), MT 13 (4-(tert-butylamino)-6-(ethylamino)-1,3,5-triazin-2-ol or 6-hydroxy-N2-ethyl-N4-tert-butyl-1,3,5-triazine-2,4-diamine), MT14 (4-amino-6-(tert-butylamino)-1,3,5-triazin-2-ol or N-tert-butyl-6-hydroxy-1,3,5-triazine-2,4-diamine), and of the unidentified metabolites LM1, LM2, LM3, LM4, LM5 and LM6 with respect to cancer, if terbuthylazine is classified under Regulation (EC) No 1272/2008 as ‘suspected of causing cancer’.